Finally, the seroreactivity assays performed in this study confirmed the high ability of the most seroreactive p53 and p63 proteoforms to discriminate CRC patients and individuals with premalignant lesions from healthy individuals, in comparison with canonical proteins. This evidence concerns the gene TP53 and colorectal carcinoma.